KIT-13

KIT-13 is an orally active plasmalogen derivative to inhibit neuroinflammation and mitochondrial DNA leakage associated with Mecp2 deficiency. KIT-13 significantly reduce neurological symptoms and improves the life span of the Rett Syndrome (RTT) model mice. KIT-13 can be used for the study of RTT and other neuroinflammation-related diseases[1].

Product Specifications

UNSPSC

12352211

Target

Mitochondrial Metabolism

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(O[C@@H](CO[P@]([O-])(OCC[NH3+])=O)COCCCCCCCCCCCCCCCCCC)=O

Molecular Formula

C43H80NO7P

Molecular Weight

754.07

References & Citations

[1]Akane Matsuda, et al. Novel plasmalogen derivative KIT-13 restores neurological function in a mouse model of Rett syndrome by reducing neuroinflammation and restoring mitochondrial function. BioRxiv. 2025 June 12.